Benzylpiperazine: the New Zealand legal perspective.

BASSINDALE, Thomas (2011). Benzylpiperazine: the New Zealand legal perspective. Drug Testing and Analysis, 3 (7-8), 428-429.

Full text not available from this repository.
Link to published version:: https://doi.org/10.1002/dta.314

Abstract

In 2005 the New Zealand Government created a new schedule of ‘Restricted Substances’ under the Misuse of Drugs Act (1975). Benzylpiperazine was the first drug to be classified as what became known informally as ‘Class D’. The rationale behind that decision and the subsequent reclassification of benzylpiperazine to Class C, in 2008, is discussed.

Item Type: Article
Research Institute, Centre or Group - Does NOT include content added after October 2018: Biomedical Research Centre
Identification Number: https://doi.org/10.1002/dta.314
Page Range: 428-429
Depositing User: Rebecca Jones
Date Deposited: 08 Feb 2012 17:01
Last Modified: 18 Mar 2021 20:30
URI: https://shura.shu.ac.uk/id/eprint/4495

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics